Advertisement

Acta Biologica Hungarica

, Volume 60, Issue 2, pp 177–183 | Cite as

Genotoxicity Study of Hypiran and Chamomilla Herbal Drugs Determined by in vivo Supervital Micronucleus Assay With Mouse Peripheral Reticulocytes

  • H. KalantariEmail author
  • A. Ashrafi Dashtearjandi
  • E. Kalantar
Article

Abstract

The growth in popularity of Over The Counter (OTC) of medicinal products or other natural sources have taken a very large share of healthcare system therefore it is essential to determine their safety as for as public health is concerned.

In this study Maximum Tolerated Dose (MTD) was obtained according to CSGMT protocol presented by the Environmental Mutagen Society of Japan. The positive group received mitomycin C in dose of 0.5 mg/kg. The peripheral blood samples before treatment (zero time) were considered as negative control. The MTD of Hypiron was 12 ml/kg and for Chamomilla was 10 ml/kg. Doses of MTD, 1/2 MTD and 1/4 MTD were considered for test groups. Then blood samples were prepared 48 hours after first administration of drugs and kept on precoated Acridine orange slides. The scoring of micronucleated reticulocytes were carried out per 2000 counted reticulocytes in each slide by fluorescent microscope. The results were statistically analyzed. Results of Hypiran were compared with negative control group and the P value was P > 0.05, but the p value of Chamomilla was P < 0.05. Also, the p value of Hypiran and Chamomilla compared with historical negative control group was less, therefore Chamomilla herbal drog can be classified as equivocul category of genotoxicity and Hypiran did not show genotoxicity.

Keywords

Micronucleus test genotoxicity Hypiran Chamomilla mitomycin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bradley, P. R. (ed.) (1992) British Herbal Compendium Volume I, British Herbal Medicine Association.Google Scholar
  2. 2.
    Chan, K. (2003) Some aspects of toxic contaminants in herbal medicines. Chemospher. 52, 1361–1371.CrossRefGoogle Scholar
  3. 3.
    Derringer, S. D., Bishop, M. E., McNamee, J. P., Hayashi, M., Suzu, T., Asano, N., Nakajima, M., Saito, J., Moore, M., Torous, D. K., Macgregor, J. T. (2006) Flow cytometric analysis of micronuclei in peripheral blood reticulocytes: I. Intra- and interlaboratory comparison with microscopic scoring. Toxicol. Sci. 94, 83–91.CrossRefGoogle Scholar
  4. 4.
    Guidelines for testing of chemicals; (1995) Protocol recommended by the CSGMT/JEMS.MMS for the short term mouse peripheral blood micronucleus test. Mutagenesi. 10, 153–159.CrossRefGoogle Scholar
  5. 5.
    Hayashi, M., Morita, T., Kodama, Y., Sofuni, T., Ishidate, M. Jr. (1990) The micronucleous assay with mouse peripheral blood reticulocytes using acriding orange coated slides. Mutat. Res. 245, 245–249.CrossRefGoogle Scholar
  6. 6.
    Kalantari, H., Larki, A., Latifi, S. M. (2007) The genotoxicity study of garlic and pasipy herbal drops by peripheral blood micronucleou test. Acta Physiol. Hung. 94, 261–266.CrossRefGoogle Scholar
  7. 7.
    Kalantari, H., Habibazar, J. H., Elliott, S. (2002) Study of the mutagenicity of “Hypiran” and “Sankol” in human blood cells and comparison with hydrogen peroxide by single cell gel electrophoresis (SCGE) or comet assay. Drugs Chem. Toxicol. 25, 141–148.CrossRefGoogle Scholar
  8. 8.
    Mavournin, K. H., Blakey, D. H., Cimino, M. C., Salamone, M. F., Heddle, J. A. (1990) The in vivo micronucleus assay in mammalian bone marrow and peripheral blood. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat. Res. 239, 29–80.CrossRefGoogle Scholar
  9. 9.
    McGuffin, M., Hobbs, C., Upton, R., Goldberg, A. (1997) American Herbal Products Association - Botanical Safety Handbook, CRC Press.Google Scholar
  10. 10.
    Nestler, G. (2002) Traditional Chinese medicine. Med. Clin. North Am. 86, 63–73.CrossRefGoogle Scholar
  11. 11.
    Piegorsch, W. W., Lockhart, A. C., Carr, G. I., Margolin, B. H., Brooks, T., Douglas, G. R., Liegibel, U. M., Suzuki, T., Thybaud, V., van Delft, J. H., Gorelick, N. J. (2001) Sources of variability in data from a positive selection lacZ transgenic mouse mutation assay: an interlaboratory study. Mutat. Res. 388, 249–289.CrossRefGoogle Scholar
  12. 12.
    Tosaki, A., Droy-Lefaix, M. T., Pali, T., Das, D. K. (1993) Effects of SOD, catalase, and a novel antiarrhythmic drug, EGB 761, on reperfusion-induced arrhythmias in isolated rat hearts. Free Radie. Biol. Med. 14, 361–370.CrossRefGoogle Scholar
  13. 13.
    Varga, E., Bodi, A., Ferdinandy, P., Droy-Lefaix, M. T., Blasig, I. E., Tosaki, A. (1999) The protective effect of EGb 761 in isolated ischemic/reperfused rat hearts: a link between cardiac function and nitric oxide production. J. Cardiovasc. Pharmacol. 34, 711–717.CrossRefGoogle Scholar
  14. 14.
    Wakata, A., Miyamae, Y., Sato, S., Suzuki, T., Morita, T., Asano, N., Awogi, T., Kondo, K., Hayashi, M. (1998) Evaluation of the rat micronucleus test with bone marrow and peripheral blood: summary of the 9th collaborative study by CSGMT/JEMS. MMS. Collaborative Study Group for the Micronucleus Test. Environmental Mutagen Society of Japan. Mammalian Mutagenicity Study Group. Environ. Mol. Mutagen. 32, 84–100.CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest 2009

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • H. Kalantari
    • 1
    Email author
  • A. Ashrafi Dashtearjandi
    • 1
  • E. Kalantar
    • 2
  1. 1.School of PharmacyAhwaz Jundishapur University of Medical SciencesAhwazIran
  2. 2.School of MedicineKordestan University of Medical SciencesSanandejIran

Personalised recommendations